EU-funded R&D project
Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment
Safe use of medication and adherence to treatment are significant public health challenges where understanding, access to accurate information, capabilities to comprehend, and trust play major roles. The worldwide research project Gravitate-Health aims for improved access and understanding of health information, for safe use of medicines, risk minimization and improved quality of life.
To that effect, Gravitate-Health will develop and test an integrated, digital, user-centric health information solution seeking to demonstrate tangible improvements in availability and understanding of health information from a set of trusted sources, starting with regulator-approved medicinal product information and the Electronic Health Record International Patient Summary (EHR-IPS).
The main outputs will be an open source digital platform and a white paper with recommendations on realistic strategies to strengthen access, understanding and future use of digital services like electronic product information (ePI) as a tool for risk minimization.
i~HD leads a work package focused on the pilot studies and their evaluation, to derive the evidence on how delivering better quality medication and health information to patients through mobile technologies can impact on their understanding of their medication, adherence to it and health outcomes. We are also contributing to the business modelling and long term sustainability strategy.
The project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945334. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations [EFPIA]. It started on 1 November 2020 for a project duration of 60 months.
Consortium Partners
Universitet i Oslo (Coordinator), Norwegian Centre for eHealth Research, Akershus Universitetssykehus, Norsk e-Helse AS, Statens Legemiddelverk, Pfizer Limited (Project Lead), Eli Lilly and Company Limited, MDSOL Europe Ltd, Datapharm Limited, Karolinska Institutet, FrisQ Holding AB, AstraZenica AB, Københavns Universitet, Trifork Public A/S, HL7 Europe, Forum European des Patients, The European Institute for Innovation through Health Data, The Synergist, UCB Biopharma SRl, Datawizard SRL, Università Cattolica del Sacro Cuore, Universidad Politécnica de Madrid, Open Evidence, Servicio Madrileño de Salud, Agencia Española de Medicamentos y Productos Sanitarios, empirica Gesellschaft für Kommunikations-und Technologieforschung mbH, HIMSS Europe GmBH, Bayer Aktiengesellschaft, Grünenthal GmBH, Trinity College Dublin, European Connected Health Alliance, Mylan IRE Healthcare Limited, Rijksinstituut voor Volksgezondheid en Milieu Agentschap Collegee ter Beoordeling van Geneesmiddelen, MINDVIEW Business Consulting and Research limited, Serviços Partilhados do Ministério da Saúde E.P.E., Guardtime OÜ, Novartis Pharma AG, F. Hoffmann – La Roche AG, Division of Clinical Informatics at Beth Israel Deaconess Medical Center
